The RegMed XB Annual Conference 2026 in Utrecht has come to a close, and for Fluidnatek, it was much more than just a date on the calendar. Represented by our colleague Pilar Salinas, we spent several intensive days fully immersed in the heart of the regenerative medicine ecosystem, engaging with the pioneers who are redefining the future of healthcare.
Our presence at RegMed XB was driven by a clear purpose: to support the transition from groundbreaking research to real-world patient impact.
The Translation Challenge
At Fluidnatek, we believe that the next generation of cell and gene therapies, tissue engineering, and advanced biomaterials depends entirely on the enabling technologies behind them. A brilliant scientific concept remains a concept until it can be manufactured under rigorous standards and moved into clinical applications.
During her interactions with researchers, clinicians, and ATMP developers, Pilar noted a common priority: bridging between proof-of-concept and clinical reality. Whether it’s developing complex scaffolds for tissue engineering or precision drug delivery systems, the consensus was clear—process control and scalability are the new frontiers.
Scaling Innovation with Precision
Our participation reinforced the vital role that electrospinning and electrospraying play in this ecosystem. These aren’t just laboratory techniques; they are scalable manufacturing platforms that offer:
- Unmatched Precision: Creating nanofibrous structures that mimic the natural extracellular matrix.
- Reproducibility: Essential for meeting the stringent requirements of regulatory bodies and clinical trials.
- Scalability: Moving from benchtop research to pilot manufacturing without losing the properties that make the material effective.
Looking Ahead
Regenerative medicine is a collaborative journey. Seeing the entire value chain—from investors to policymakers and scientists—gathered in one place reminds us why we do what we do. At Fluidnatek, we are committed to providing the advanced processing technology that turns visionary research into tangible medical solutions.
The conference may be over, but the work of scaling the future of medicine continues. We are ready to help you navigate the manufacturing challenges of your next breakthrough.
ESP